Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT05237401 |
Other study ID # |
222112021 |
Secondary ID |
|
Status |
Recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
April 21, 2022 |
Est. completion date |
January 2027 |
Study information
Verified date |
September 2023 |
Source |
King's College London |
Contact |
Luigi Nibali |
Phone |
3701093729 |
Email |
luigi.nibali[@]kcl.ac.uk |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Periodontitis is an inflammatory disease of the tooth-supporting apparatus, which leads to
attachment and bone loss and eventually to tooth loss if treatment is not provided.
When the periodontitis-related bone loss affects the area of root separation in molars, a
furcation involvement (FI) is created. This represents a challenge in the treatment of
periodontally-compromised molars, affecting the majority of patients with periodontitis.
Based on a prevalence of severe forms of periodontitis in the UK and worldwide of about 10%
of the population and on previous studies, we can assume that at least 5-10% of the general
population are affected by FI.
Different treatment modalities are advocated for the treatment of FI, including non-surgical
maintenance, resective (bone recontouring) and regenerative (reconstruction of bone and
attachment) surgical treatments or tooth extraction. It has clearly emerged that FI at least
doubles the risk of tooth loss. However, in the case of advanced through-and-through loss of
attachment and bone in the furcation area (FI degree III), the clinician is often faced with
a very difficult treatment decision, without being able to draw on much evidence from the
literature. Interestingly, there are no randomised controlled trials exploring the most
appropriate treatment for advanced furcation involvement. This has been highlighted in a
recent systematic review commissioned by the European Federation of Periodontology.
Description:
Subject recruitment All patients will be recruited from Periodontal Clinics at the
participating centres in United Kingdom (Ravenscourt Dental Practice, 5 Ravenscourt avenue,
Germany (University Hospital of Berlin, Bonn, Frankfurt and Greifswald), Sweden (Malmo),
Spain (Santiago de Compostela), Italy (Torino) and Australia (Brisbane). When a potentially
suitable patient is identified in the clinics, the assigned hospital consultant (or
equivalent outside the UK) will inform him/her of the study and ask if the patient is
interested in discussing this with a member of the research team. Then a member of the
research team will approach the patient, provide more information about the study procedures
and will give them an information sheet about the study. If the patient agrees to take part,
they will be offered a baseline appointment. If they need more time to consider
participation, they will be contacted by phone by a member of the periodontology research
team within 1 week to enquire about their willingness to take part in the study and to give
them the opportunity to ask any questions about the study. If all inclusion/exclusion
criteria cannot be verified at the new patient clinic appointment, a review appointment prior
to baseline will be offered. Each subject will be part of the study for approximately 5
years.
At the time of subject recruitment in addition to information about the study; the overall
management plan will be discussed with the patient. The responsible consultant (or
equivalent) will provide information about the treatment of the non-study sites and what
additional treatment will be provided for those areas. This will commence once the study
sites have been treated. If any other dental treatment is required before the baseline visit
(e.g. fillings or extractions), as judged by the responsible consultant (or equivalent), such
treatment will be carried out prior to baseline.
Screening Procedures Potential new patients which may be suitable for the study will be
screened alongside all other patients attending Periodontology clinics at the participating
centres and accepted based upon the inclusion and exclusion criteria above.
Randomisation Procedures Randomisation for test or control treatment will be carried out
between baseline (visit 1) and visit 2. The randomisation service 'Sealed envelope' will be
used in each centre for randomisation and to ensure allocation concealment. A sealed envelope
will be enclosed with the patient's notes by personnel not directly involved in the study.
The therapist will be informed about treatment allocation by opening the envelope at the
beginning of the treatment appointment.
For each centre patients will be allocated to the two treatment groups using a randomisation
list that was previously prepared by the study statistician. For important influencing
factors ('centre') stratified randomisation will be carried out as recommended , especially
in case of small sample sizes.
Clinical periodontal examination Dichotomous (no/yes) full mouth plaque scores (FMPS) will be
recorded, identifying tooth surfaces revealing the visual presence of plaque following the
use of plaque-disclosing tablets. Periodontal measurements will be taken by the calibrated
examiner at six sites per tooth using a manual University of North Carolina (UNC-15)
periodontal probe. The following periodontal measurements will be taken full mouth at 6 sites
per tooth: probing pocket depth (PPD), recession of the gingival margin from the
cemento-enamel junction (CEJ), dichotomous (no/yes) bleeding on probing (BoP) . Recession
will be recorded as a negative number if the gingival margin is above CEJ (or the assigned
reference e.g. restorative margin); and as a positive number (incl. 0) if margin is on (0) or
below CEJ (>0). Further, tooth mobility (no/yes and degree 1, 2 or 3, horizontal furcation
involvement using a Nabers probe (no/yes and degree 1, 2 or 3) and finally vertical furcation
involvement (no/yes and class A, B or C) measured with a UNC-15 probe will be recorded.
Clinical attachment levels (CAL) will be calculated as PPD + recession. The amount of
keratinized gingiva by the test furcation will be recorded. This is part of standard care.
Sub-gingival plaque sampling
Sub-gingival plaque samples will be collected from:
- test site (TS): preferably buccal surface of furcation site; alternatively, mesial
furcation site in maxillary furcation if buccal furcation is not degree III
- control site (CS): ideally, symmetrical contralateral site in case of no furcation
involvement. Alternatively, another site with PPD<4mm and no bleeding on probing will be
chosen and recorded.
For example, LR6 buccal (furcation III) as test site and LL6 buccal (no FI) as control site.
Plaque samples will be collected from the selected TS and CS at baseline and then following
treatment at 4 months, at 8 months, at 12 months and at all subsequent 12-monthly follow-ups
(a total of 8 time-points).
Ahead of the sampling procedure, the supra-gingival plaque will be carefully removed, the
site isolated with cotton rolls and gently dried. A sterile curette will then be inserted to
the bottom of the pocket and removed after a single stroke and the content will be placed in
a test tube containing a buffer solution such as TE buffer solution (Cat No. 93283
Sigma-Aldrich) and stored at -80ÂșC until the time of analysis. The aim of taking sub-gingival
plaque samples at these time points is to assess the composition of the sub-gingival
microbiota before and after treatment in test and control sites.
Data Recording/Reporting The results of the laboratory analyses will be recorded in encrypted
databases according to standard procedures.
Adverse Events (AE) An AE is any untoward medical occurrence in a subject to whom a medicinal
product has been administered, including occurrences which are not necessarily caused by or
related to that product. An AE can therefore be any unfavourable and unintended sign
(including an abnormal laboratory finding), symptom or disease temporarily associated with
study activities.
Notification and reporting Adverse Events or Reactions If the AE is not defined as SERIOUS,
the AE is recorded in the study file and the participant is followed up by the research team.
The AE is documented in the participants' medical notes (where appropriate) and the CRF.
Statistical analyses Comprehensive descriptive analyses will be done for primary and
secondary endpoints. Time trajectories of primary and secondary endpoints within treatment
groups will be graphically assessed. Also, distributions of primary and secondary endpoints
within groups over time points will be graphically shown.
The analysis level is the tooth (one target molar per patient is included). In case of more
than 1 suitable molar per patient, the 'study molar' will be chosen based on deepest PPD (or
deepest CAL in case of same PPD).